Quantcast

Latest placebo Stories

2014-04-29 23:18:12

Listen Live on Coast to Coast with George Noory as Dr. Joe introduces the release of his new book You Are the Placebo: Making Your Mind Matter. Also, Join Dr. Joe for a live You Are the Placebo Teleclass with Insight Events at 6pm PST Sign up free here - http://insighteventsusa.com/placebo-teleclass/. (PRWEB) April 29, 2014 In You Are the Placebo: Making Your Mind Matter, Dr. Joe Dispenza explores the history, the science, and the practical applications of the so-called placebo effect....

2014-04-29 16:31:14

-- UCLA Researcher Reports Adjunctive Trimesta was Associated with Reduced Relapse Rate of 47 Percent -- ROCKVILLE, Md., April 29, 2014 /PRNewswire/ -- Synthetic Biologics, Inc. (NYSE MKT: SYN), a developer of novel anti-infective biologic and drug candidates targeting specific pathogens that cause serious infections and diseases, reported today that the University of California, Los Angeles (UCLA) School of Medicine announced preliminary, positive topline data from the Phase II...

2014-04-29 12:33:25

Palm tocotrienols may slow the progression of brain-degenerating white matter lesions MINNEAPOLIS, April 29, 2014 /PRNewswire/ -- While you may know about your brain's gray matter, did you also know that about 50 percent of your brain is made of white matter? The health of your brain's white matter affects how well it learns and functions. This is also the area of the brain most often affected by stroke. Now results of a two-year human clinical study published in the American...

2014-04-28 08:32:18

TORONTO, April 28, 2014 /PRNewswire/ - Highland Therapeutics Inc. ("Highland"), an emerging pharmaceutical company, today announced that its wholly owned subsidiary has begun enrolment in a Phase III study of HLD-200, the Company's novel formulation of methylphenidate, in pediatric patients with Attention-Deficit Hyperactivity Disorder ("ADHD"). The study, "A Phase III Clinical Endpoint Evaluation Study ("CEES") Examining the Safety and Efficacy of HLD-200 in Pediatric Subjects with...

2014-04-28 08:27:50

New Data Demonstrate that NUEDEXTA® may Provide Early PBA Symptom Remission ALISO VIEJO, Calif., April 28, 2014 /PRNewswire/ -- Avanir Pharmaceuticals, Inc. (NASDAQ: AVNR) today announced that data from its CNS therapeutics franchise, specifically in its pseudobulbar affect (PBA) and migraine development programs will be presented at the 66(th) American Academy of Neurology (AAN) Annual Meeting in Philadelphia. In addition, an article in the peer-reviewed publication, US Neurology,...

2014-04-26 16:20:49

Clinical Trials Point Toward 'ATX-101' as Potential Noninvasive Solution for Reduction of Submental Fat SAN FRANCISCO, April 26, 2014 /PRNewswire-USNewswire/ -- Skin laxity and fat buildup under the chin is a common concern among facial aesthetic patients. Although surgery has long been the mainstay for reducing fat in this area, which is also known as the submental region, new research being presented at the Annual Meeting of the American Society for Aesthetic Plastic Surgery (ASAPS) being...

2014-04-25 08:27:40

WOODCLIFF LAKE, N.J., April 25, 2014 /PRNewswire/ -- Eisai Inc. announced today that six abstracts highlighting data analyses for FYCOMPA(TM) (perampanel) will be presented at the 66(th) annual American Academy of Neurology (AAN) meeting, taking place in Philadelphia, PA from April 26( )- May 3. http://photos.prnewswire.com/prnvar/20120413/MM87168LOGO "Eisai and its epilepsy franchise are committed to expanding its knowledge of current products and developing new medications for the...

2014-04-24 16:29:59

PHILADELPHIA, April 24, 2014 /PRNewswire-USNewswire/ -- A new study suggests that targeting B cells, which are a type of white blood cell in the immune system, may be associated with reduced disease activity for people with multiple sclerosis (MS). The study is released today and will be presented at the American Academy of Neurology's 66th Annual Meeting in Philadelphia, April 26 to May 3, 2014. For the study, 231 people with relapsing-remitting MS received either a placebo or one...

2014-04-23 12:29:10

MINNEAPOLIS, April 23, 2014 /PRNewswire-USNewswire/ -- Two new studies may offer hope for people with migraine. The two studies released today will be presented at the American Academy of Neurology's 66th Annual Meeting in Philadelphia, April 26 to May 3, 2014. Both studies involve drugs that are aimed at preventing migraine attacks from occurring, rather than stopping the attacks once they have started. These studies are the first to test monoclonal antibodies for the prevention of...

Drug Treatment And Weight Loss Can Restore Vision Loss: Study
2014-04-23 12:11:19

NIH/National Eye Institute An inexpensive glaucoma drug, when added to a weight loss plan, can improve vision for women with a disorder called idiopathic intracranial hypertension (IIH), according to a study funded by the National Institutes of Health. IIH, also called pseudotumor cerebri, predominantly affects overweight women of reproductive age. An estimated 100,000 Americans have it, and the number is rising with the obesity epidemic. The most common symptoms are headaches and...


Word of the Day
jument
  • A beast of burden; also, a beast in general.
'Jument' ultimately comes from the Latin 'jugum,' yoke.
Related